RNA NanoMed
Volume 1
Volume 2

RNA NanoMed

Due to the rapid growth of the field of RNA and its potential applications including RNA therapeutics, it is encouraging to have an RNA journal that advances the field by bridging the fundamental research and application of RNA. The prediction that RNA will become the third milestone in drug development has become a reality.  The establishment of an RNA journal related to this field by the International Society for RNA Nanotechnology and Nanomedicine (ISRNN) will be in line with the vision and mission of the society.

About Us

Coming issue

Editorial for the Inaugural Issue

The recent discovery of the critical role of  RNA in biological systems has revolutionized our understanding of molecular biology. It was found that only 1.5% of the human genome encodes for proteins, while the remaining 98.5% of the human genome mainly codes for small or long non-coding RNA. These unexpected findings have significantly transformed life sciences. Recent FDA approval of RNAi drugs and COVID-19 mRNA vaccines has highlighted the potential of RNA therapeutics in clinics. These breakthroughs underscore RNA's emergence as a cornerstone of modern medicine, as documented by Nobel Prize awards in Medicine or Physiology in 2023 and 2024. I am pleased that my 2014 publication predicted that RNA would be the third milestone in pharmaceutical drug development, which is now being realized.

View

Coming Issue

Review Articles
Nucleic-Acid Based Approaches for Detection of microRNA

Akhilesh Kumar Gupta, Alexey V. Krasnoslobodtsev

ISRNN (RNA NanoMed.)
[View the article]

DOI: https://doi.org/10.59566/ISRNN.2025.0201A

Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy

Tanvi S. Bolarum1, 2 and Marina A. Dobrovolskaia1,*

ISRNN (RNA NanoMed.)
[View the article]

DOI: https://doi.org/10.59566/ISRNN.2025.0201B

Original Research Articles

Targeting EGFR self-assembling RNA nanoparticles co-delivering paclitaxel and miRNA21 inhibitors for the treatment of head and neck tumors

Yuejuan Che+,1,2,3,4, Zhuohao Wen+,5, Jiali Shou6, Yujuan Li*,4, Miao Zhou*,5, Chang Du*,1,2,3

ISRNN (RNA NanoMed.)
[View the article]

DOI: https://doi.org/10.59566/ISRNN.2025.0201C

RNA Nanoparticles Harboring Radioisotopes or Other Imaging Molecules for Spontaneous Tumor Targeting for Early Cancer Diagnosis

Daniel W. Binzel1†, Congcong Xu1†, Katherine Binzel2, Arijit Ghosh3, Adam Pippin3, Xin Li1, Mario Sechi4, Michael V. Knopp3, Krishan Kumar5, Peixuan Guo1*

ISRNN (RNA NanoMed.)
[View the article]

DOI: https://doi.org/10.59566/ISRNN.2025.0201D

.

VOLUME 1 (2024)

Review Articles:
  1. Harnessing Computational Approaches for RNA-Targeted Drug Discovery
  2. Targeted Delivery of Potent Chemical Drugs and RNAi to Drug-Resistant Breast Cancer Using RNA-Nanotechnology and RNA-Ligand Displaying Extracellular vesicles
  3. Applications of Surface Plasmon Resonance for Advanced Studies Involving Nucleic Acids
Original Research Articles:
  1. Co-incubation of Short Amphiphilic Peptides with Dicer Substrate RNAs Results in β-Sheet Fibrils for Enhanced Gene Silencing in Cancer Cells
  2. The Reduction of Traumatic Spinal Cord Secondary Injury by Anti-RhoA siRNA Functionalized Nucleic Acid Nanoparticles (NANPs)
  3. pH-responsive bond as a linker for the release of chemical drugs from RNA–drug complexes in endosome or lysosome
  4. Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment